Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

Clinical markers of response in metastatic renal cell carcinoma (mRCC) are lacking. Low hemoglobin (Hb) is associated with poor outcomes in the IMDC risk score. This study evaluates the role of Hb as a marker of treatment outcomes in mRCC. This multicenter retrospective study evaluated 276 patients...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical genitourinary cancer 2023-08, Vol.21 (4), p.e242-e251
Hauptverfasser:	Yang, Yu-Hsuen, Ansel, Sonam, Meerveld-Eggink, Aafke, Jackson-Spence, Francesca, Rallis, Kathrine, Brian, Paul, Choy, Julia, Sng, Christopher, Adeniran, Philip, Amin, Jubel, Galope, Sarah, Anderson, Naomi, Bex, Axel, Powles, Thomas, Venugopal, Balaji, Szabados, Bernadett
Format:	Artikel
Sprache:	eng
Schlagworte:	Immunotherapy Personalised medicine Predictive marker Risk stratification Targeted therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!